AIS
Lundbeck scraps stroke drug
December 18, 2014Research and Development, Sales and Marketing AIS, DIAS, Lundbeck, acute ischemic stroke, desmoteplase, stroke
Lundbeck has stopped development of its investigational stroke drug desmoteplase following disappointing results from its Phase III studies. The DIAS-3 …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
